Huaqiang Zhou,Yan Huang, Zeting Qiu,Hongyun Zhao,Wenfeng Fang, Yunpeng Yang,Yuanyuan Zhao, Xue Hou,Yuxiang Ma, Shaodong Hong, Ting Zhou, Yaxiong Zhang

International journal of cancer, (2018)

WOSBibtex

Optimal prophylaxis of chemotherapy-induced nausea and vomiting for moderately emetogenic chemotherapy: a meta-analysis.

Yaxiong Zhang,Xue Hou,Rong Zhang,Gang Chen,Yan Huang,Yunpeng Yang,Yuanyuan Zhao,Wenfeng Fang,Shaodong Hong,Shiyang Kang,Ting Zhou, Zhonghan Zhang

Future oncology (London, England), (2018)

WOSBibtex

The efficacy of first-line chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis.

Shu-Xiang Ma,Ting Zhou,Yan Huang,Yun-Peng Yang,Jian-Hua Zhan,Ya-Xiong Zhang, Zhong-Han Zhang,Yuan-Yuan Zhao,Wen-Feng Fang,Yu-Xiang Ma,Li-Kun Chen,Hong-Yun Zhao

Annals of translational medicine, no. 11 (2018): 201

WOSBibtex

The Efficacy and Toxicity of Lobaplatin-contained Chemotherapy in Extensive-stage Small-cell Lung Cancer.

Ning-Ning Zhou,Yuan-Yuan Zhao, Lin-Zhu Zhai, Chao-Mei Ruan,Yun-Peng Yang,Yan Huang,Xue Hou,Li-Kun Chen,Ting Zhou,Li Zhang

Journal of Cancer, no. 13 (2018): 2232-2236

Cited by1WOSBibtex

Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.

Wenfeng Fang,Yunpeng Yang,Yuxiang Ma,Shaodong Hong, Lizhu Lin, Xiaohui He,Jianping Xiong, Ping Li,Hongyun Zhao,Yan Huang,Yang Zhang,Likun Chen

The Lancet. Oncology, (2018)

Cited by5WOSBibtex

Inhibiting eEF-2 kinase-mediated autophagy enhanced the cytocidal effect of AKT inhibitor on human nasopharyngeal carcinoma.

Yuan-Yuan Zhao,Ying Tian, Lin Liu, Jian-Hua Zhan,Xue Hou, Xi Chen,Ting Zhou,Yan Huang,Li Zhang

Drug design, development and therapy, (2018): 2655-2663

WOSBibtex

P038 Docosapentaenoic Acid and Lung Cancer Risk: A Mendelian Randomisation Study

J. Liu, H. Zhou, Y. Zhang,Y. Huang,W. Fang,Y. Yang,S. Hong,G. Chen, S. Zhao, X. Chen, Z. Zhang, J. Shen

Journal of Thoracic Oncology, no. 12 (2018)

Bibtex

Chemotherapy Near the End of Life for Chinese Patients with Solid Malignancies.

Jin Sheng,Ya-Xiong Zhang,Xiao-Bo He,Wen-Feng Fang,Yun-Peng Yang, Gui-Nan Lin, Xuan Wu, Ning Li, Jing Zhang, Lin-Zhu Zhai,Yuan-Yuan Zhao,Yan Huang

The oncologist, no. 1 (2017): 53-60

Cited by1WOSBibtex

The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer.

Yaxiong Zhang,Gang Chen, Xi Chen,Wenfeng Fang, Fei Gao,Yunpeng Yang,Yuanyuan Zhao,Yuxiang Ma,Shaodong Hong, Zhonghan Zhang, Siyu Miao, Manli Wu

Journal of Cancer, no. 10 (2017): 1865-1871

Cited by3WOSBibtex

Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-based Subtypes.

Li Zhang, Kenzie D MacIsaac, Ting Zhou,Pei-Yu Huang, Chunlin Xin, Jason R Dobson, Kun Yu, Derek Y Chiang, Yue Fan, Marc Pelletier, Yan Wang, Savina Jaeger

Molecular cancer research : MCR, (2017)

Cited by7WOSBibtex

Fruitful steps in the prevention of chemotherapy-induced nausea and vomiting (CINV) over the past 30 years: A historical comparison of patients enrolled in clinical trials during different antiemetic times.

Zhihuang Hu,Li Zhang,Yuxiang Ma,Wenhua Liang,Yan Huang,Hongyun Zhao,Yuanyuan Zhao,Cong Xue,Xuan Wu,Wenfeng Fang

Journal of Clinical Oncology, (2017)

Bibtex

Pharmacokinetic and pharmacogenetic analysis in patients with advanced nasopharyngeal carcinoma (NPC) treated with 5-flurouracil (5-FU) and cisplatin.

Yuxiang Ma,Hongyun Zhao,Liping Zhao,Yunpeng Yang,Cong Xue,Xuan Wu,Wenhua Liang,Yuanyuan Zhao,Wenfeng Fang,Tao Qin

Journal of Clinical Oncology, (2017)

Bibtex

Multicenter, randomized, controlled, open-label study of bevacizumab combined with carboplatin and paclitaxel versus carboplatin and paclitaxel in patients with metastatic nasopharyngeal carcinoma.

Li Zhang,Yan Huang,Tao Qin,Hongyun Zhao,Likun Chen,Peiyu Huang,Xue Hou,Yuanyuan Zhao,Wenfeng Fang,Yuxiang Ma,Yunpeng Yang,Ting Zhou

Journal of Clinical Oncology, (2017)

Bibtex

Correction to: Pharmacokinetic and Pharmacodynamic Analyses of 5-Fluorouracil in East-Asian Patients with Nasopharyngeal Carcinoma

Yuxiang Ma, Yuehao Lin, Benyan Zou, Wanli Liu,Yang Zhang,Liping Zhao,Yan Huang,Yunpeng Yang,Wenfeng Fang,Yuanyuan Zhao,Jin Sheng,Tao Qin

Clinical Pharmacokinetics, no. 1 (2017): 103-104

Bibtex

Serum low-density lipoprotein and low-density lipoprotein expression level at diagnosis are favorable prognostic factors in patients with small-cell lung cancer (SCLC)

Ting Zhou,Jianhua Zhan,Wenfeng Fang,Yuanyuan Zhao,Yunpeng Yang,Xue Hou, Zhonghan Zhang, Xiaobo He,Yaxiong Zhang,Yan Huang,Li Zhang

BMC Cancer, no. 1 (2017): 269

Cited by3Bibtex

Pretreatment Albumin/Globulin Ratio Predicts the Prognosis for Small-Cell Lung Cancer.

Ting Zhou,Xiaobo He,Wenfeng Fang,Jianhua Zhan,Shaodong Hong,Tao Qin,Yuxiang Ma,Jin Sheng,Ningning Zhou,Yuanyuan Zhao,Yan Huang,Li Zhang

Medicine, no. 12 (2016): e3097-e3097

Cited by22WOSBibtex

Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy.

Zhihuang Hu,Weiching Liang,Yunpeng Yang,Dorothy Keefe,Yuxiang Ma,Yuanyuan Zhao,Cong Xue,Yong Huang,Hongyun Zhao,Likun Chen,Alexandre Chan,Lifan Zhang

Medicine, no. 2 (2016): e2476-e2476

Cited by5WOSBibtex

Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo.

Cong Xue,Ying Tian,Jing Zhang,Yuanyuan Zhao,Jianhua Zhan,Wenfeng Fang,Li Zhang

Drug Design Development and Therapy, (2016): 1173-1180

Bibtex

Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma.

Yan Huang,Wenhua Liang,Yunpeng Yang,Liping Zhao,Hongyun Zhao,Xuan Wu,Yuanyuan Zhao,Yang Zhang,Li Zhang

BMC cancer, no. 1 (2016): 464

WOSBibtex

A retrospective analysis of the clinicopathological and molecular characteristics of pulmonary blastoma.

Yuan-Yuan Zhao, Lin Liu,Ting Zhou, Ning-Ning Zhou,Yun-Peng Yang,Xue Hou, Yong Li,Hong-Yun Zhao,Yan Huang,Li Zhang

OncoTargets and therapy, (2016): 6915-6920

WOSBibtex

A multicenter, retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China.

Yunpeng Yang,Yuxiang Ma,Jin Sheng,Yan Huang,Yuanyuan Zhao,Wenfeng Fang,Shaodong Hong,Ying Tian,Cong Xue,Li Zhang

Chinese journal of cancer, no. 1 (2016): 40-40

Cited by6WOSBibtex

Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients.

Shaodong Hong,Nan Chen,Wenfeng Fang,Jianhua Zhan, Qing Liu,Shiyang Kang,Xiaobo He, Lin Liu,Ting Zhou, Jiaxing Huang, Ying Chen,Tao Qin

Oncoimmunology, no. 3 (2016): e1094598-e1094598

Cited by19WOSBibtex

Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: A network meta-analysis

Yaxiong Zhang,Jin Sheng,Yunpeng Yang,Wenfeng Fang,Shiyang Kang, Yang He,Shaodong Hong,Jianhua Zhan,Yuanyuan Zhao,Cong Xue,Yuxiang Ma,Ting Zhou

Oncotarget, no. 15 (2016): 20093-20108

Bibtex

Relation of the BIM deletion polymorphism to intrinsic EGFR-TKI resistance of Chinese patients with EGFR mutant advanced non-small cell lung cancer.

Shuang Xin,Yuanyuan Zhao,Yuxiang Ma,Xueding Wang,Yan Huang,Hongyun Zhao,Chen Zhu,Yunpeng Yang,Li Zhang,Min Huang

Journal of Clinical Oncology, (2016)

Bibtex

The expression of plakoglobin is a potential prognostic biomarker for patients with surgically resected lung adenocarcinoma.

Xiaobo He,Ting Zhou,Guangwei Yang,Wenfeng Fang, Zelei Li,Jianhua Zhan,Yuanyuan Zhao, Zhibin Cheng,Yan Huang,Hongyun Zhao,Li Zhang

Oncotarget, no. 12 (2016): 15274-87

WOSBibtex

In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma.

Cong Xue,Ying Tian,Jing Zhang,Yuanyuan Zhao,Jianhua Zhan,Wenfeng Fang,Li Zhang

Drug design, development and therapy, (2016): 1299-1306

WOSBibtex

Benefit from thoracic radiotherapy in patients with extensive-disease small-cell lung cancer with elevated lactate dehydrogenase.

Tao Qin, Ningning Zhou,Yin-Duo Zeng,Xiaoxiao Dinglin,Yuanyuan Zhao, Huai Liu,Likun Chen

OncoTargets and therapy, (2016): 1095-103

WOSBibtex

Correlation of polymorphisms of JAK and STAT with gefitinib-induced hepatotoxicity in patients with non-small cell lung cancer.

Shuang Xin,Yuxiang Ma,Xueding Wang,Yan Huang,Chen Zhu,YuanYuan Zhao,Li Zhang,Min Huang

Journal of Clinical Oncology, (2015)

Bibtex

Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma

Jing Zhang,Ying Tian,Cong Xue,Zhihuang Hu,Li Zhang,Yuanyuan Zhao

(2015)

Bibtex

QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC

Yunpeng Yang,Yuxiang Ma,Yan Huang,Yuanyuan Zhao,Wenfeng Fang,Shaodong Hong,Ying Tian,Cong Xue,Jin Sheng,Li Zhang

Scientific Reports, (2015)

Cited by2Bibtex

The Effectiveness of RECIST on Survival in Patients with NSCLC Receiving Chemotherapy with or without Target Agents as First-Line Treatment

Li Zhang,Hongyun Zhao, Jieying Ge,Yuanyuan Zhao,Wenfeng Fang,Yang Zhang,Zhihuang Hu,Lie Zheng,Ting Zhou

Scientific Reports, (2015)

Bibtex

PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival

Wenfeng Fang,Shaodong Hong,Nan Chen,Xiaobo He,Jianhua Zhan,Tao Qin,Ting Zhou,Zhihuang Hu,Yuxiang Ma,Yuanyuan Zhao,Ying Tian,Yunpeng Yang

Oncotarget, (2015)

Cited by21Bibtex

Advanced Lung Cancer Inflammation Index, a New Prognostic Score, Predicts Outcome in Patients With Small-Cell Lung Cancer.

He Xiaobo,Zhou Ting,Yang Yunpeng,Hong Shaodong,Zhan Jianhua,Hu Zhihuang,Fang Wenfeng,Qin Tao,Ma Yuxiang,Zhao Yuanyuan,Cheng Zhibin,Huang Yan

Clinical lung cancer, (2015)

Cited by9WOSBibtex

The Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis From 9 Randomized Controlled Trials.

Jialian Sheng,Y P Yang,Y Y Zhao,Tao Qin, Z H Hu,Tong Zhou, Y X Zhang,S D Hong,Y X Ma,H Y Zhao, Yue Huang,Li Zhang

Medicine, (2015)

Cited by5Bibtex

Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma.

Jianwei Zhang,Wenfeng Fang,Tao Qin,Yunpeng Yang,Shaodong Hong,Wenhua Liang,Yuxiang Ma,Hongyun Zhao,Yan Huang,Cong Xue,Peiyu Huang,Zhihuang Hu

Medical oncology (Northwood, London, England), no. 3 (2015): 86-86

Cited by46WOSBibtex

The effectiveness of RECIST on survival in patients with NSCLC receiving chemotherapy with or without target agents as first-line treatment.

Ting Zhou,Lie Zheng,Zhihuang Hu,Yang Zhang,Wenfeng Fang,Yuanyuan Zhao,Jieying Ge,Hongyun Zhao,Li Zhang

Scientific reports, (2015): 7683-7683

Cited by2WOSNATUREBibtex

Efficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer: A Meta-Analysis and Systemic Review

Jin Sheng,Yunpeng Yang, Bijun Yang,Yuanyuan Zhao,Yuxiang Ma,Shaodong Hong,Yaxiong Zhang,Hongyun Zhao,Yan Huang,Li Zhang

Medicine, no. 31 (2015)

Bibtex

A systemic inflammation-based prognostic scores (mGPS) predicts overall survival of patients with small-cell lung cancer.

Ting Zhou,Shaodong Hong,Zhihuang Hu,Xue Hou,Yan Huang,Hongyun Zhao,Wenhua Liang,Yuanyuan Zhao,Wenfeng Fang,Xuan Wu,Tao Qin,Li Zhang

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, no. 1 (2015): 337-343

Cited by16WOSBibtex

Pharmacogenetic determinants of gefitinib trough concentration in patients with non-small cell lung cancer.

Shuang Xin,Yuxiang Ma,Xueding Wang,Yan Huang,Jiali Li,YuanYuan Zhao, Lingyan Chen, Rong Hu,Min Huang,Li Zhang

Journal of Clinical Oncology, (2014)

Bibtex

Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials.

Shaodong Hong,Wenfeng Fang,Wenhua Liang,Yue Yan,Ting Zhou,Tao Qin,Xuan Wu,Yuxiang Ma,Yuanyuan Zhao,Yunpeng Yang,Zhihuang Hu,Cong Xue

OncoTargets and therapy, (2014): 1851-1867

Cited by12WOSBibtex

Phase I dose-escalation study of aflibercept plus docetaxel in nasopharyngeal carcinoma and other solid tumors.

Yan Huang,Ben-Yan Zou,Li-Ping Zhao,Hong-Yun Zhao,Yuan-Yuan Zhao,Cong Xue,Jian-Wei Zhang,Fei Xu,Li-Kun Chen,Jun-Ling Liu,Zhi-Huang Hu,Xuan Wu

Future oncology (London, England), no. 16 (2014): 2579-2591

Cited by1WOSBibtex

The good pain management (GPM) ward program in China and its impact on Chinese cancer patients: the SYSUCC experience.

Yunpeng,Yang,Yuxiang,Ma,Yan,Huang,Yuanyuan,Zhao,Fei,Xu,Ying,Tian

Chinese journal of cancer, no. 7 (2014): 323-329

Cited by2WOSBibtex

An investigation of symptom burden and quality of life in Chinese chemo-naïve advanced lung cancer patients by using the Instrument-Cloud QOL System.

Yuxiang Ma,Yunpeng Yang,Yan Huang,Hongyun Zhao,Xue Hou,Ying Tian,Yuanyuan Zhao,Cong Xue,Wenfeng Fang,Xuan Wu,Zhihuang Hu,Wenhua Liang

Lung cancer (Amsterdam, Netherlands), no. 3 (2014): 301-306

Cited by6WOSBibtex

1219TiPOPEN, SINGLE ARM TRIAL OF ERLOTINIB AS THE 2ND/3RD LINE TREATMENT IN ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR WILD TYPE AND C-MET NEGATIVE EXPRESSION (ML28941, C-TONG 1306)

Zhifei Li,Taogeng Zhou,Yan Huang,Heyun Zhao,Long Chen,Y Y Zhao,Weichuan Fang, P Y Yang,Xinyu Hou,Chunyi Xue, X Y Ma,Zhengguo Hu

Annals of oncology : official journal of the European Society for Medical Oncology, no. suppl_4 (2014)

WOSBibtex

Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.

Wenhua Liang,Xuan Wu,Wenfeng Fang,Yuanyuan Zhao,Yunpeng Yang,Zhihuang Hu,Cong Xue,Jing Zhang,Jianwei Zhang,Yuxiang Ma,Ting Zhou,Yue Yan

PloS one, no. 2 (2014): e85245-e85245

Cited by87WOSBibtex

A systemic inflammation-based prognostic scores (mGPS) to predict overall survival of patients with small cell lung cancer.

Li Zhang,Ting Zhou,Zhihuang Hu,Xue Hou,Yan Huang,Hongyun Zhao,YuanYuan Zhao,Wenhua Liang,Wenfeng Fang

Journal of Clinical Oncology, (2014)

Bibtex

The prognostic nutritional index (PNI) predicts overall survival of small-cell lung cancer patients.

Shaodong Hong,Ting Zhou,Wenfeng Fang,Cong Xue,Zhihuang Hu,Tao Qin,Yanna Tang,Yue Chen,Yuxiang Ma,Yunpeng Yang,Xue Hou,Yan Huang

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, no. 5 (2014): 3389-3397

Cited by39WOSBibtex

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy.

Wenfeng Fang,Jianwei Zhang,Shaodong Hong,Jianhua Zhan,Nan Chen,Tao Qin,Yanna Tang,Yaxiong Zhang,Shiyang Kang,Ting Zhou,Xuan Wu,Wenhua Liang

Oncotarget, no. 23 (2014): 12189-12202

Cited by119WOSBibtex

Clinicopathological and prognostic significance of CD24 overexpression in patients with gastric cancer: a meta-analysis.

Jing-Xun Wu,Yuan-Yuan Zhao,Xuan Wu,Han-Xiang An

PloS one, no. 12 (2014): e114746-e114746

Cited by5WOSBibtex

A large-scale cross-sectional study of ALK rearrangements and EGFR mutations in non-small-cell lung cancer in Chinese Han population.

Shaodong Hong,Wenfeng Fang,Zhihuang Hu,Ting Zhou,Yue Yan,Tao Qin,Yanna Tang,Yuxiang Ma,Yuanyuan Zhao,Cong Xue,Yan Huang,Hongyun Zhao

Scientific reports, (2014): 7268-7268

Cited by16WOSNATUREBibtex

Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo.

Yuan-Yuan Zhao,Ying Tian,Jing Zhang,Fei Xu,Yun-Peng Yang,Yan Huang,Hong-Yun Zhao,Jian-Wei Zhang,Cong Xue,Michael H Lam, Li Yan,Zhi-Huang Hu

Drug design, development and therapy, (2014): 1827-1837

Cited by8WOSBibtex

The anticancer effect of lobaplatin on human nasopharyngeal carcinoma cells in vitro

TIAN Ying,CHEN Xinggui,HUANG Ying,HUANG He,ZHAO Yuanyuan,LIN Tongyu

Chinese Clinical Oncology, pp.8-13, (2013)

Bibtex

SPARC expression and prognostic value in non-small cell lung cancer.

Yan Huang,Jing Zhang,Yuan-Yuan Zhao,Wei Jiang,Cong Xue,Fei Xu,Hong-Yun Zhao,Yang Zhang,Li-Ping Zhao,Zhi-Huang Hu,Zhi-Wen Yao,Qian-Yong Liu

Chinese journal of cancer, no. 11 (2012): 541-548

Cited by13WOSSCOPUSBibtex

Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib.

Fei Xu,Jingxun Wu,Cong Xue,Yuanyuan Zhao,Wei Jiang,Liping Lin,Xuan Wu,Yachao Lu,Hua Bai,Jiasen Xu,Guanshan Zhu,Li Zhang

OncoTargets and therapy, (2012): 439-447

Cited by31WOSBibtex

Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma.

Li-Ping Zhao,Cong Xue,Jian-Wei Zhang,Zhi-Huang Hu,Yuan-Yuan Zhao,Jing Zhang,Yan Huang,Hong-Yun Zhao,Li Zhang

Chinese journal of cancer, no. 10 (2012): 476-483

Cited by8WOSSCOPUSBibtex

Immediate versus delayed topotecan after first-line therapy in small cell lung cancer]

Wei Jiang,Yang Zhang,Hongyun Zhao,Guangchuan Xu,Liping Lin,Yuanyuan Zhao,Cong Xue,Li Zhang

Zhongguo fei ai za zhi = Chinese journal of lung cancer, no. 3 (2010): 211-215

Cited by4WOSSCOPUSBibtex

Predictive factors for response and survival of gefitinib-treated locally advanced or metastatic non-small cell lung cancer patients: a retrospective analysis of two phase II clinical trials]

Yuan-Yuan Zhao,Yang Zhang,Hong-Yun Zhao,Jing-Xun Wu,Wei Jiang,Cong Xue,Li Zhang

Ai zheng = Aizheng = Chinese journal of cancer, no. 6 (2009): 626-631

Cited by3WOSSCOPUSBibtex

A case report and literature review of double primary cancer in nasopharynx and lung.]

Jingxun Wu,Fenghua Wang,Peiyu Huang,Yang Zhang,Jieling Weng,Yuanyuan Zhao,Wei Jiang,Cong Xue,Li Zhang

Zhongguo fei ai za zhi = Chinese journal of lung cancer, no. 1 (2009): 86-89

Cited by4WOSSCOPUSBibtex

Analysis of the relationship between the response after the First-line chemotherapy and the survival in the advanced non-small cell lung cancer.]

Liping Lin,Xiaojuan Xiang,He Huang,Hongyun Zhao,Yang Zhang,Jingxun Wu,Yuanyuan Zhao,Xuan Wu,Li Zhang

Zhongguo fei ai za zhi = Chinese journal of lung cancer, no. 3 (2008): 333-338

Cited by4WOSSCOPUSBibtex

The relationship between circulating VEGF level and outcome of advanced Chinese NSCLC treated with gefitinib

Yuanyuan Zhao, C. Q. Zhang, L. P. Lin,Xuan Wu,J. X. Wu,Fenghua Wang,Hongyun Zhao,Z. Z. Guan,Lin Zhang

Journal of Clinical Oncology, (2008): 19074-19074

Bibtex

View All

Base Info Papers Patents Projects